A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients
A Phase 2a, Multi-center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112 in Patients With Stable Atherothrombotic Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Chula Vista, California, United States, 91911
- Study Site
-
-
Florida
-
Jacksonville, Florida, United States, 32209
- Study Site
-
Miami, Florida, United States, 33126
- Study Site
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- Study Site
-
Madisonville, Kentucky, United States, 42431
- Study Site
-
-
Maine
-
Auburn, Maine, United States, 04210
- Study Site
-
-
Maryland
-
Baltimore, Maryland, United States, 21215
- Study Site
-
-
Michigan
-
Petoskey, Michigan, United States, 49770
- Study Site
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Study Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Study Site
-
-
South Dakota
-
Rapid City, South Dakota, United States, 57701
- Study Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female aged 18 years to 80 years.
- Subjects must have documented evidence of a history of atherosclerotic coronary artery disease/surgical revascularization.
- Subjects on a stable medication regimen.
- Body weight 50 kg or greater at screening.
Exclusion Criteria:
- Moderate/severe heart failure or renal impairment.
- Uncontrolled hyperglycemia in subjects with type 1 or type 2 diabetes.
- Receipt of the combination of omeprazole and clopidogrel within 1 month of randomization.
- Subjects whose medical history, condition or medication regimen may interfere with the evaluation of the safety and tolerability of CSL112 (for example significantly altered electrocardiogram (ECG) waveform, hepatobiliary disease, malignancy, thrombocytopenia, etc.)
- Known hypersensitivity to the product components
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
Single intravenous doses of normal saline (0.9%)
|
|
Experimental: CSL112
|
Single escalating intravenous doses of CSL112
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety
Time Frame: 14 days
|
The frequency of study product-related adverse events
|
14 days
|
|
Clinically significant elevation of alanine aminotransferase (ALT) or aspartate aminotransferase (AST)
Time Frame: 14 days
|
Number of subjects with clinically significant elevation of ALT or AST
|
14 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pharmacokinetic profile of apolipoprotein A-I (apoA-I)
Time Frame: 9 days
|
Plasma apoA-I concentration with and without baseline correction
|
9 days
|
|
Plasma apoA-I area under the curve (AUC)
Time Frame: 9 days
|
9 days
|
|
|
Plasma apoA-I Cmax
Time Frame: 9 days
|
9 days
|
|
|
Plasma apoA-I Tmax
Time Frame: 9 days
|
9 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Dr. Denise D'Andrea, CSL Limited
Publications and helpful links
General Publications
- Zheng B, Duffy D, Tricoci P, Kastrissios H, Pfister M, Wright SD, Gille A, Tortorici MA. Pharmacometric analyses to characterize the effect of CSL112 on apolipoprotein A-I and cholesterol efflux capacity in acute myocardial infarction patients. Br J Clin Pharmacol. 2021 Jun;87(6):2558-2571. doi: 10.1111/bcp.14666. Epub 2020 Dec 23.
- Tricoci P, D'Andrea DM, Gurbel PA, Yao Z, Cuchel M, Winston B, Schott R, Weiss R, Blazing MA, Cannon L, Bailey A, Angiolillo DJ, Gille A, Shear CL, Wright SD, Alexander JH. Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial. J Am Heart Assoc. 2015 Aug 25;4(8):e002171. doi: 10.1161/JAHA.115.002171.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- CSLCT-HDL-10-70a
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.